Fig. 4: ExLR-based d-signature for the diagnosis of early stage BC. | npj Breast Cancer

Fig. 4: ExLR-based d-signature for the diagnosis of early stage BC.

From: Plasma extracellular vesicle long RNA profiles in the diagnosis and prediction of treatment response for breast cancer

Fig. 4: ExLR-based d-signature for the diagnosis of early stage BC.The alternative text for this image may have been generated using AI.

a ExLR d-signature scores in healthy (n = 41), benign (n = 19), and BC (n = 112). b ExLR d-signature scores in BC patients with stage I (n = 28), II (n = 35), III (n = 15), and IV (n = 34). c–e ROC for the performance of the exLR d-signature in BC with early stages (Stage I/II) compared to control (c), healthy (d), and benign (e). f, g ExLR d-signature scores in BC patients with different serum CA15-3 (f) and CEA (g) statuses. AUC area under the curve, SD standard deviation, CI confidence interval.

Back to article page